Skip to main content
Equibles

Affinity Asset Advisors, LLC

Position in QURE — uniQure N.V.

CIK 1773195 NEW YORK, NY
Back to QURE Full portfolio

Position in QURE

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$8,060,500
+$8,060,500 QoQ
Shares Held
175,000
Ownership
0.277%
of shares outstanding
% of Portfolio
0.41%
of 13F equity value
Holder Rank
#60
of 255 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in QURE Over Time

Shares Held

Position Value (USD)

Derivatives in QURE

reported options exposure · as of Jun 30, 2026
CallValue
$9,212,000
CallShares
200,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Affinity Asset Advisors, LLC holds $1,842,784,374 across 87 Biotechnology names. QURE ranks #50 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ROIV
Roivant Sciences Ltd.
 3,750,000 $132,712,500
2 APGE
Apogee Therapeutics, Inc.
 987,000 $131,004,510
3 SYRE
Spyre Therapeutics, Inc.
 1,279,134 $113,561,516
4 XENE
Xenon Pharmaceuticals Inc.
 1,595,000 $96,274,200
5 ERAS
Erasca, Inc.
 5,250,000 $96,180,000
6 INSM
INSMED Inc
 650,000 $69,303,000
7 PRAX
Praxis Precision Medicines, Inc.
 185,000 $61,936,150
8 ORKA
Oruka Therapeutics, Inc.
 590,000 $56,150,300

All Filings in QURE

Export CSV
9 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $8,060,500 175,000
2026-06-30 $9,212,000 200,000
2026-03-31 $4,905,000 300,000
2025-12-31 $19,144,000 800,000
2025-12-31 $1,196,500 50,000
2025-09-30 $17,511,000 300,000
2025-06-30 $1,881,900 135,000
2025-06-30 $1,394,000 100,000
2025-03-31 $4,240,000 400,000